UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announces that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay US $650m upfront and up to US $500m in potential future milestone payments.
Read the full article: UCB to Acquire Neurona Therapeutics //
Source: https://www.prnewswire.com/news-releases/ucb-to-acquire-neurona-therapeutics-advancing-its-innovative-leadership-in-epilepsy-through-regenerative-science-302746167.html